Hemlibra’s Benefits for Hem A With Inhibitors Upheld in STASEY Trial

Hemlibra’s Benefits for Hem A With Inhibitors Upheld in STASEY Trial

300088

Hemlibra’s Benefits for Hem A With Inhibitors Upheld in STASEY Trial

Two years of preventive treatment with Genentech’s Hemlibra (emicizumab) safely and effectively lowered the number of bleeds in people with hemophilia A and clotting factor VIII (FVIII) inhibitors, according to final data from the Phase 3b STASEY trial. Development of antibodies against the therapy (anti-drug antibodies) was also rare and temporary, and did not affect treatment effectiveness, researchers reported. These findings, which are consistent with those from previous approval-enabling clinical trials, were presented at the…

You must be logged in to read/download the full post.